Big Pharma Eyes Strategic Acquisitions in 2025 to Counter Patent Expirations - PRESS AI WORLD
PRESSAI
Recent Posts
side-post-image
side-post-image
Economy

Big Pharma Eyes Strategic Acquisitions in 2025 to Counter Patent Expirations

share-iconFriday, January 03 comment-icon2 weeks ago 5 views
News sources:
businessinsiderBUSINESSINSIDER
Big Pharma Eyes Strategic Acquisitions in 2025 to Counter Patent Expirations

Credited from: BUSINESSINSIDER

  • Big Pharma is set to ramp up **acquisitions in 2025** as key drugs face patent expirations, notably **Merck's Keytruda** and **Pfizer's Eliquis**.
  • The loss of exclusivity for these drugs is expected to prompt significant revenue declines, with **Keytruda** generating **$25 billion** in 2023 alone.
  • **Chris Roop**, an M&A expert, predicts increased activity in the biopharma sector, especially in emerging markets like **obesity** and **oncology**.
  • Obesity is anticipated to become a **$100 billion to $150 billion market**, driving companies to seek new treatments in this lucrative area.
  • Major pharmaceutical firms are also eyeing advancements in **precision oncology** and **cardiovascular drugs**, indicating a broad strategy for future growth.

For more details, visit the original article here.

SHARE THIS ARTICLE:

nav-post-picture
nav-post-picture